Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC10 Phase 1 Safety, PK, and Food Effect in Healthy Subjects
NCT05523141Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC10 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Number of participants with Treatment Emergent Adverse Events in MAD up to 12 days, Number of Participants With Clinically Significant Change From Baseline in Vital Signs in MAD up to 12 days and 1 more. Started Oct 2022; status: completed.
02
Drugs
ASC10
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05523141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523141.